此前一天，国家医保局发布《2025年国家基本医疗保险、生育保险和工伤保险药品目录及商业健康保险创新药 品目录调整工作方案》等系列文件。其中，最受市场关注的是新增的商保创新药目录。 创新药板块，迎来利好消息！ 7月11日，2025年国家基本医疗保险、生育保险和工伤保险药品目录及商业健康保险创新药品目录调整正式启 动。 二级市场上，创新药板块近期持续走强。7月11日，Wind创新药指数涨超2%，益方生物涨超18%，常山药业涨 超16%，药明康德、凯莱英涨停。多家券商表示，继续看好创新药及相关产业链。 2025年医保目录调整正式启动 据新华社消息，7月11日，2025年国家基本医疗保险、生育保险和工伤保险药品目录及商业健康保险创新药品 目录调整正式启动，符合条件的申报主体可在7月11日至20日期间，通过国家医保服务平台进行网上申报。 今年首次新增的商保创新药目录，主要聚焦创新程度高、临床价值大、患者获益显著，但因超出"保基本"定位 暂时无法纳入基本目录的药品，助力健全多层次用药保障体系，更好满足人民群众多元化的用药需求，为创新 药发展提供更充足的经济支撑。 此前一天，即7月10日，国家医保局发布《2025年国家基本 ...

Group 1: Innovation Drug Sector - The innovation drug concept is experiencing a resurgence, with Kangchen Pharmaceutical hitting the daily limit up [3] - Other companies in the sector such as Changshan Pharmaceutical and Boteng Co. saw increases exceeding 10% [3] - The overall market sentiment is positive, with the A-share market showing slight gains [1][2] Group 2: Stablecoin Concept - The stablecoin concept is also seeing significant gains, with Guoao Technology reaching a daily limit up of 20% [3] - Other companies like Geer Software and Greenland Holdings also hit their daily limits [3] - The Shanghai Municipal State-owned Assets Supervision and Administration Commission is focusing on the development trends of cryptocurrencies and stablecoins [3] Group 3: Real Estate Sector - The real estate sector is showing strong performance, with companies like Yucheng Development achieving five consecutive limit ups [4] - Policies to stabilize the housing market are being implemented, with over 150 measures introduced to optimize housing provident fund policies [4] - Other real estate companies such as Tianbao Infrastructure and Greenland Holdings also saw significant gains [4] Group 4: Pork Sector - The pork sector is experiencing notable activity, with Zhenghong Technology hitting the daily limit up [5] - Other companies like Dongrui Co. and Muyuan Foods are also among the top gainers in this sector [5]

Core Viewpoint - The innovative drug concept continues to show strong performance, with significant stock price increases for companies such as Boteng Co. and Changshan Pharmaceutical, which rose over 15% [1] Group 1: Stock Performance - Boteng Co. and Changshan Pharmaceutical saw stock increases of over 15% [1] - WuXi AppTec experienced a nearly 9% rise [1] - Other companies like Kylin Pharmaceutical, Guangsheng Pharmaceutical, and Yifang Bio also saw stock increases of over 5% [1] Group 2: Policy Announcement - On July 10, the National Healthcare Security Administration announced the adjustment plan for the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalogs, as well as the Commercial Health Insurance Innovative Drug Catalog [1] - The plan specifies that the adjustments to the basic medical insurance drug catalog and the establishment of the commercial health insurance innovative drug catalog will occur simultaneously in 2025 [1]

创业板融资余额连增期间，融资余额增加的有513只，增幅超20%的有38只，融资余额增幅最大的是家 联科技，最新融资余额5071.71万元，其间增幅152.21%，其次是晶雪节能、菲利华，最新融资余额分别 为4743.12万元、1.67亿元，其间增幅分别为84.29%、80.53%。融资余额下降的有420只，降幅超10%的 有37只，融资余额降幅最大的是屹通新材，最新融资余额6598.37万元，其间下降30.43%，其次是鸿铭 股份、瑞晨环保，最新融资余额分别为1980.28万元、2816.10万元，其间降幅分别为27.89%、25.74%。 其间融资余额变动幅度居前个股 | 代码 | 简称 | 最新融资余额（万 | 其间增减 | 代码 | 简称 | 最新融资余额 | 其间增减 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 元） | （%） | | | （万元） | （%） | | 301193 | 家联科 | 5071.71 | 152.21 | 300930 | 屹通新 | 6598.37 | -30.43 | | | 技 | | | | ...

Group 1 - The core point of the article highlights the net inflow of main funds into various industries, with a total of 65.68 billion yuan flowing into the Shanghai and Shenzhen markets on July 8, including 59.68 billion yuan into the ChiNext market and 57.92 billion yuan into the CSI 300 index [2] - Among the 13 industries with net inflows, the electronics industry led with a net inflow of 40.76 billion yuan, followed by the computer industry with 26.6 billion yuan, and the communication, power equipment, and non-bank financial industries each exceeding 16 billion yuan [2] - In contrast, 18 industries experienced net outflows, with the pharmaceutical and biological industry seeing the largest outflow of over 15 billion yuan, followed by public utilities, national defense, and basic chemicals, each with outflows exceeding 5 billion yuan [3] Group 2 - A total of 77 stocks had net inflows exceeding 1 billion yuan, with 9 stocks seeing inflows over 4 billion yuan. Zhongyou Capital topped the list with a net inflow of 9.01 billion yuan, closing at the daily limit [4] - Pengding Holdings ranked second with a net inflow of 6.41 billion yuan, while other notable stocks with significant inflows included Zhongji Xuchuang, N Yitang, Dongfang Caifu, and Inspur Information, with inflows of 5.85 billion yuan, 5.16 billion yuan, 5.16 billion yuan, and 4.86 billion yuan respectively [6] - On the other hand, 37 stocks had net outflows exceeding 1 billion yuan, with Changshan Pharmaceutical leading the outflow at 8.3 billion yuan, followed by Jinyi Culture, Rongfa Nuclear Power, and Shaoneng Shares [7][8] Group 3 - At the end of the trading day, there was a net inflow of 35.8 billion yuan, with the ChiNext market contributing 12.97 billion yuan and the CSI 300 index contributing 13.24 billion yuan [9] - Among the stocks with significant end-of-day inflows, Dongfang Caifu led with a net inflow of 2.21 billion yuan, followed by Hangang Co., Zhongzhou Special Materials, and Ningde Times [10][11] - Conversely, 7 stocks experienced end-of-day net outflows exceeding 0.6 billion yuan, with Changshan Pharmaceutical again leading with a net outflow of 1.65 billion yuan, closing down 12.8% [12]

7月8日，沪指上涨0.70%，深成指上涨1.47%，创业板指上涨2.39%，沪深300指数上涨0.84%。可交易A 股中，上涨的有4282只，占比79.27%，下跌的981只。 资金面上，今日主力资金全天净流入154.50亿元。其中，创业板主力资金净流入60.36亿元；科创板主力 资金净流入4.56亿元；沪深300成份股主力资金净流入95.15亿元。 分行业来看，申万所属的一级行业中，今日上涨的有29个，涨幅居前的行业为通信、电力设备，涨幅为 2.89%、2.30%。跌幅居前的行业为公用事业、银行，跌幅为0.37%、0.24%。 行业资金流向方面，今日有14个行业主力资金净流入，电子行业主力资金净流入规模居首，该行业今日 上涨2.27%，全天净流入资金74.37亿元，其次是电力设备行业，日涨幅为2.30%，净流入资金为36.78亿 元。 （文章来源：证券时报网） 主力资金净流出的行业有17个，公用事业行业主力资金净流出规模居首，今日下跌0.37%，全天净流出 资金22.97亿元，其次是医药生物行业，今日涨幅为0.31%，净流出资金为22.85亿元，净流出资金较多 的还有国防军工、银行、商贸零售等行业。 今日各 ...

2025.07. 08 作者 | 一财资讯 7月8日，A股三大指数收盘集体上涨，截至收盘，上证指数涨0.7%，深证成指涨1.47%，创业板指 涨2.39%。 | 代码 | 名称 | 两日图 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | --- | --- | | 000001 | 上证指数 | and now | 3497.48c | 24.35 | 0.70% | | 399001 | 深证成指 | plant | 10588.39c | 152.89 | 1.47% | | | 创业板指 | | | | | | 399006 | | w/ | 2181.08 c | 50.89 | 2.39% | 沪深两市全天成交额1.45万亿，全市场超4200只个股上涨。 | | | 净流出方面，常山药业、金一文化、信雅达遭抛售8.23亿元、7.67亿元、5.29亿元。 【机构观点】 盘面上，光伏板块集体大涨，BC电池、硅能源、PCB概念走高，水电概念小幅走弱。 具体来看，光伏板块集体爆发，通威股份、钧达股份、亿晶光电等10余股涨停。 PCB等算力方向继续走强，国际复材、逸豪新 ...

截至7月7日收盘，减肥药概念下跌1.10%，位居概念板块跌幅榜前列，板块内，科兴制药、一品红、甘 李药业等跌幅居前，股价上涨的有17只，涨幅居前的有泰恩康、*ST三圣、蓝晓科技等，分别上涨 4.12%、3.21%、2.31%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 中船系 | 5.23 | 同花顺果指数 | -1.53 | | 生物质能发电 | 2.83 | 重组蛋白 | -1.42 | | 2025中报预增 | 2.77 | 减肥药 | -1.10 | | 虚拟电厂 | 2.62 | CRO概念 | -1.07 | | 跨境支付(CIPS) | 2.36 | AI PC | -1.02 | | 抽水蓄能 | 2.26 | AI手机 | -0.99 | | 超超临界发电 | 2.20 | 中国AI 50 | -0.98 | | 租售同权 | 2.20 | 芬太尼 | -0.85 | | 柔性直流输电 | 2.00 | 共封装光学(CPO) | -0.82 | | 特高压 | 1.98 | 创新药 | ...

沪指7月3日上涨0.18%，申万所属行业中，今日上涨的有24个，涨幅居前的行业为电子、电力设备，涨 幅分别为1.69%、1.38%。医药生物行业位居今日涨幅榜第三。跌幅居前的行业为煤炭、交通运输，跌 幅分别为1.16%、0.28%。 资金面上看，两市主力资金全天净流出45.11亿元，今日有9个行业主力资金净流入，电子行业主力资金 净流入规模居首，该行业今日上涨1.69%，全天净流入资金78.20亿元，其次是医药生物行业，日涨幅为 1.35%，净流入资金为13.82亿元。 主力资金净流出的行业有22个，机械设备行业主力资金净流出规模居首，全天净流出资金23.17亿元， 其次是基础化工行业，净流出资金为19.08亿元，净流出资金较多的还有国防军工、传媒、电力设备等 行业。 医药生物行业今日上涨1.35%，全天主力资金净流入13.82亿元，该行业所属的个股共474只，今日上涨 的有388只，涨停的有12只；下跌的有83只。以资金流向数据进行统计，该行业资金净流入的个股有231 只，其中，净流入资金超亿元的有6只，净流入资金居首的是华海药业，今日净流入资金2.69亿元，紧 随其后的是长春高新、众生药业，净流入资金分别 ...

Core Viewpoint - Changshan Pharmaceutical has gained significant attention due to the approval of its weight loss indication for Aibennate, with its stock price rising substantially in recent days, reflecting the growing interest in GLP-1 receptor agonists in the market [3][4][7] Company Summary - Changshan Pharmaceutical's stock price closed at 50.69 yuan per share on June 24, 2023, marking a 2.55% increase, and has seen a total increase of 136.71% since the beginning of 2025 [3][4] - The company has faced continuous losses for two consecutive years, with net losses of 1.24 billion yuan in 2023 and 249 million yuan in 2024, primarily due to declining prices in the heparin market [5][8] - The approval for Aibennate's clinical trials is a step towards diversifying the company's revenue sources, which have heavily relied on heparin products [7][8] Industry Summary - The GLP-1 market is rapidly expanding, with a projected global market size of approximately 52.83 billion USD in 2024, reflecting a 46% year-on-year growth [14] - Major players in the GLP-1 market include Novo Nordisk and Eli Lilly, which dominate with significant market shares of 55% and 31%, respectively [14] - There are over 50 candidates in clinical development for GLP-1 receptor agonists in China, indicating a highly competitive landscape [15][17] - The competition is intensifying, with multiple companies racing to develop innovative formulations, including multi-target, ultra-long-acting, and oral dosage forms [17]